Physician profile
Anil K Rustgi
NPI 1609919588
$4,207.93
in general payments reported to CMS, 2019-2025
7 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2021: $500 · 2022: $84.28 · 2023: $101 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $123.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,000.00 | 2025 | |
| Aurobindo Pharma USA, INC. | $1,500.00 | 2019 | |
| Intra-Sana Laboratories | $500.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $100.77 | 2023 | Calquence |
| Gilead Sciences, INC. | $84.28 | 2022 | |
| Pentax of America, INC. | $22.88 | 2025 | Pentax Medical, C2 Cryoballoon Focal Controller, C2 Cryoballoon |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Rustgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.